As the world’s manufacturing hub, China has boost its pharmaceutical market over the past decade to become one of the fastest growing and most competitive markets.
5 policies in 2019 will affect China’s pharmaceutical market in 2020, which mainly involve China’s national medical insurance payment and pharmaceutical product cost control.
In addition to China, LENVIMA is approved for use in the treatment of HCC in Japan, the United States, Europe, and other countries in Asia and around the world